(Q37778263)

23 August 2017

1 reference

title

What is causing the mortality in treating the anemia of chronic kidney disease: erythropoietin dose or hemoglobin level? (English)

1 reference

chronic renal insufficiency

23 August 2017

1 reference

1 reference

Ajay K. Singh

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20689425

17 June 2024

language of work or name

1 reference

1 September 2010

1 reference

full work available at URL

23 August 2017

https://journals.lww.com/10.1097/MNH.0b013e32833cf1d6

1 reference

https://api.crossref.org/works/10.1097/MNH.0B013E32833CF1D6

Current Opinion in Nephrology and Hypertension

17 June 2024

published in

1 reference

23 August 2017

volume

19

1 reference

23 August 2017

issue

5

1 reference

23 August 2017

page(s)

420-424

1 reference

Correction of anemia with epoetin alfa in chronic kidney disease

23 August 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1097/MNH.0B013E32833CF1D6

A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.

17 June 2024

2

1 reference

https://api.crossref.org/works/10.1097/MNH.0B013E32833CF1D6

The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin

17 June 2024

3

1 reference

https://api.crossref.org/works/10.1097/MNH.0B013E32833CF1D6

Normalization of hemoglobin level in patients with chronic kidney disease and anemia

17 June 2024

4

1 reference

https://api.crossref.org/works/10.1097/MNH.0B013E32833CF1D6

Hematocrit was not validated as a surrogate end point for survival among epoetin-treated hemodialysis patients

17 June 2024

6

1 reference

https://api.crossref.org/works/10.1097/MNH.0B013E32833CF1D6

Mechanism of increased mortality risk with erythropoietin treatment to higher hemoglobin targets

17 June 2024

7

1 reference

https://api.crossref.org/works/10.1097/MNH.0B013E32833CF1D6

Associations between Changes in Hemoglobin and Administered Erythropoiesis-Stimulating Agent and Survival in Hemodialysis Patients

17 June 2024

9

1 reference

https://api.crossref.org/works/10.1097/MNH.0B013E32833CF1D6

The new FDA label for erythropoietin treatment: how does it affect hemoglobin target?

17 June 2024

12

1 reference

https://api.crossref.org/works/10.1097/MNH.0B013E32833CF1D6

Anemia-induced increase in the bleeding time: implications for treatment of nonsurgical blood loss

17 June 2024

13

1 reference

https://api.crossref.org/works/10.1097/MNH.0B013E32833CF1D6

Hyperviscosity in polycythemia vera and other red cell abnormalities

17 June 2024

14

1 reference

https://api.crossref.org/works/10.1097/MNH.0B013E32833CF1D6

High-dose erythropoietin alters platelet reactivity and bleeding time in rodents in contrast to the neuroprotective variant carbamyl-erythropoietin (CEPO)

17 June 2024

16

1 reference

https://api.crossref.org/works/10.1097/MNH.0B013E32833CF1D6

Endothelial activation markers in anemic non-dialysis chronic kidney disease patients.

17 June 2024

17

1 reference

https://api.crossref.org/works/10.1097/MNH.0B013E32833CF1D6

Cytoprotective doses of erythropoietin or carbamylated erythropoietin have markedly different procoagulant and vasoactive activities.

17 June 2024

18

1 reference

https://api.crossref.org/works/10.1097/MNH.0B013E32833CF1D6

Mechanism of erythropoietin-induced hypertension

17 June 2024

19

1 reference

https://api.crossref.org/works/10.1097/MNH.0B013E32833CF1D6

Normalization of hematocrit in hemodialysis patients with cardiac disease does not increase blood pressure

17 June 2024

20

1 reference

https://api.crossref.org/works/10.1097/MNH.0B013E32833CF1D6

Safety of ferumoxytol in patients with anemia and CKD

17 June 2024

21

1 reference

https://api.crossref.org/works/10.1097/MNH.0B013E32833CF1D6

Administration of parenteral iron and mortality among hemodialysis patients

17 June 2024

22

1 reference

https://api.crossref.org/works/10.1097/MNH.0B013E32833CF1D6

The non-haematopoietic biological effects of erythropoietin

17 June 2024

23

1 reference

https://api.crossref.org/works/10.1097/MNH.0B013E32833CF1D6

The therapeutic potential of erythropoiesis-stimulating agents for tissue protection: a tale of two receptors.

17 June 2024

24

1 reference

https://api.crossref.org/works/10.1097/MNH.0B013E32833CF1D6

Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes

17 June 2024

25

1 reference

https://api.crossref.org/works/10.1097/MNH.0B013E32833CF1D6

Comparative mortality risk of anemia management practices in incident hemodialysis patients

17 June 2024

26

1 reference

https://api.crossref.org/works/10.1097/MNH.0B013E32833CF1D6

Epoetin requirements predict mortality in hemodialysis patients

17 June 2024

27

1 reference

https://api.crossref.org/works/10.1097/MNH.0B013E32833CF1D6

Erythropoietin, iron depletion, and relative thrombocytosis: a possible explanation for hemoglobin-survival paradox in hemodialysis

17 June 2024

28

1 reference

https://api.crossref.org/works/10.1097/MNH.0B013E32833CF1D6

Anemia management and association of race with mortality and hospitalization in a large not-for-profit dialysis organization

17 June 2024

29

1 reference

https://api.crossref.org/works/10.1097/MNH.0B013E32833CF1D6

Effect of Epoetin alfa dose changes on hemoglobin and mortality in hemodialysis patients with hemoglobin levels persistently below 11 g/dL

17 June 2024

30

1 reference

https://api.crossref.org/works/10.1097/MNH.0B013E32833CF1D6

Estimated effect of epoetin dosage on survival among elderly hemodialysis patients in the United States

17 June 2024

31

1 reference

https://api.crossref.org/works/10.1097/MNH.0B013E32833CF1D6

Relationship between epoetin alfa dose and mortality: findings from a marginal structural model

17 June 2024

32

1 reference

https://api.crossref.org/works/10.1097/MNH.0B013E32833CF1D6

17 June 2024

Identifiers

1 reference

23 August 2017

1 reference